Karyopharm Therapeutics Inc.
KPTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $44 | $38 | $30 | $31 |
| % Growth | 16.1% | 26.4% | -1.7% | – |
| Cost of Goods Sold | $2 | $1 | $1 | $1 |
| Gross Profit | $42 | $37 | $29 | $29 |
| % Margin | 95.2% | 97.2% | 95.7% | 95.6% |
| R&D Expenses | $31 | $33 | $35 | $33 |
| G&A Expenses | $0 | $28 | $27 | $27 |
| SG&A Expenses | $27 | $28 | $27 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $57 | $61 | $62 | $60 |
| Operating Income | -$15 | -$24 | -$33 | -$31 |
| % Margin | -34.6% | -64.3% | -110.8% | -102.4% |
| Other Income/Exp. Net | -$18 | -$13 | $10 | $0 |
| Pre-Tax Income | -$33 | -$37 | -$23 | -$31 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$33 | -$37 | -$23 | -$31 |
| % Margin | -75.2% | -98.2% | -78.2% | -100.8% |
| EPS | -3.82 | -4.32 | -2.77 | -3.67 |
| % Growth | 11.6% | -56% | 24.5% | – |
| EPS Diluted | -3.82 | -4.32 | -2.77 | -3.67 |
| Weighted Avg Shares Out | 9 | 9 | 8 | 8 |
| Weighted Avg Shares Out Dil | 9 | 9 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $10 | $11 | $11 | $11 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$23 | -$26 | -$12 | -$20 |
| % Margin | -51.2% | -68.3% | -41.2% | -64.2% |